Myelofibrosis Clinical Trials

Recruiting myelofibrosis studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat myelofibrosis. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting myelofibrosis studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting myelofibrosis trials

Within

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

for Myelofibrosis

Sponsor: United Lincolnshire Hospitals NHS Trust

Sex: All·Age: 18 - 99

Code: NCT07424950·Phase 2

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

for Myelofibrosis

1 site in Salt Lake City

Sponsor: University of Utah

Sex: All·Age: 18+

Code: NCT07521046·Phase 1

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

for Myelofibrosis

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07623161·Phase 3

Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

for Myelofibrosis

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT07498205·Phase 4

Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

for Myelofibrosis

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18 - 45·Accepts healthy volunteers

Code: NCT07608666·Phase 1

QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

for Myelofibrosis

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18 - 45·Accepts healthy volunteers

Code: NCT07708272·Phase 1

A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

for Myelofibrosis

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18+

Code: NCT07551427·Phase 2

Apply to this trial

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

for Secondary AML

3 sites incl. Duarte

Sponsor: Aspera Biomedicines, Inc.

Sex: All·Age: 18+

Code: NCT07250646·Phase 1

Apply to this trial

Therapeutic RSK1 Targeting in Myelofibrosis

for Myelofibrosis

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT07379125·Phase 1

Apply to this trial

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

for Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

3 sites incl. Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT07020533·Phase 1

Apply to this trial

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

for Myelofibrosis

3 sites incl. Westwood

Sponsor: John Mascarenhas

Sex: All·Age: 18+

Code: NCT07447817·Phase 2

To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

for Myelofibrosis

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT07480824·Phase 1

Apply to this trial

Momelotinib During and After HCT in Myelofibrosis

for Myelofibrosis

1 site in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT07104799·Phase 1

Apply to this trial

Research Platform Myelofibrosis and Anemia

for Primary Myelofibrosis

Sponsor: iOMEDICO AG

Sex: All·Age: 18+

Code: NCT06976918

Apply to this trial

Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis

for Myelodysplastic Syndrome

Sponsor: Hospices Civils de Lyon

Sex: All·Age: 18+

Code: NCT06781099

Apply to this trial

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

for Polycythemia Vera

2 sites incl. Chicago

Sponsor: MPN Research Foundation

Sex: All·Age: 18+

Code: NCT07362225

Apply to this trial

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

for Myelofibrosis

1 site in Orange

Sponsor: University of California, Irvine

Sex: All·Age: 18+

Code: NCT07281781·Phase 1, Phase 2

Apply to this trial

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

for AML (Acute Myelogenous Leukemia)

13 sites incl. Birmingham

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: 18 - 66

Code: NCT06859424·Phase 2

Apply to this trial

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

for Polycythemia Vera

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sex: All·Age: 18+

Code: NCT06923670

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

for Myelofibrosis

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Sex: All·Age: 18+

Code: NCT06605586·Phase 1, Phase 2

Apply to this trial

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

for Myelofibrosis

9 sites incl. Boston

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT06773195·Phase 1, Phase 2

Apply to this trial

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

for Myelofibrosis

Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Sex: All·Age: 18 - 100

Code: NCT06533813

Apply to this trial

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

for Splenomegaly

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18 - 75

Code: NCT06345495·Phase 2

Apply to this trial

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

for Myelofibrosis

Sponsor: Ryvu Therapeutics SA

Sex: All·Age: 18+

Code: NCT06397313·Phase 2

Apply to this trial

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

for Hematologic Malignancy

1 site in Baltimore

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All·Age: 18+

Code: NCT06398457·EARLY_Phase 1

Apply to this trial

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

for Acute Lymphoblastic Leukemia

3 sites incl. Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT06059391·Phase 2

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

58 sites incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3

Apply to this trial

A Study of GLB-001 in Patients With Myeloid Malignancies

for Polycythemia Vera

Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT06378437·Phase 1

Apply to this trial

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

for Thrombocythemia, Essential

4 sites incl. Ann Arbor

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06351631·Phase 3

Apply to this trial

A Telehealth Advance Care Planning Intervention

for Myeloid Malignancy

1 site in Rochester

Sponsor: University of Rochester

Sex: All·Age: 60+

Code: NCT05875805

Apply to this trial

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

for Myelofibrosis

7 sites incl. Duarte

Sponsor: Karyopharm Therapeutics Inc

Sex: All·Age: 18+

Code: NCT05980806·Phase 2

Apply to this trial

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

for Clonal Cytopenia of Undetermined Significance

2 sites in Los Angeles

Sponsor: University of Southern California

Sex: All·Age: 18+

Code: NCT06063486·Phase 2

Apply to this trial

Haplo-HSCT for Myelofibrosis

for Myelofibrosis

Sponsor: Peking University People's Hospital

Sex: All·Age: All ages

Code: NCT06674382

Apply to this trial

A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

for Myelofibrosis

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18+

Code: NCT06122831·Phase 1, Phase 2

Apply to this trial

18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.

for Myelofibrosis

Sponsor: First Affiliated Hospital of Zhejiang University

Sex: All·Age: 18 - 80

Code: NCT06164561

Apply to this trial

AlloHCT With PegINFa for Myelofibrosis

for Myelofibrosis

1 site in Salt Lake City

Sponsor: University of Utah

Sex: All·Age: 18+

Code: NCT05535764·Phase 1

Apply to this trial

Allo HSCT Using RIC and PTCy for Hematological Diseases

for Acute Myelogenous Leukemia

1 site in Minneapolis

Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All·Age: Up to 75

Code: NCT05805605·Phase 2

Apply to this trial

Clonal Architecture of ASXL1-mutated Myelofibrosis

for Myelofibrosis

Sponsor: University Hospital, Angers

Sex: All·Age: 18+

Code: NCT05710211

Apply to this trial

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

for Myelofibrosis

1 site in New York

Sponsor: Marina Kremyanskaya

Sex: All·Age: 18+

Code: NCT05025488·Phase 1

Apply to this trial

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

for Myelofibrosis

4 sites incl. Sacramento

Sponsor: Cellenkos, Inc.

Sex: All·Age: 18+

Code: NCT05423691·Phase 1

Apply to this trial

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

for Castrate Resistant Prostate Cancer

6 sites incl. Phoenix

Sponsor: Epigenetix, Inc.

Sex: All·Age: 18+

Code: NCT05488548·Phase 1

Apply to this trial

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

4 sites incl. Birmingham

Sponsor: Telios Pharma, Inc.

Sex: All·Age: 18+

Code: NCT05280509·Phase 1, Phase 2

Apply to this trial

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

for Myelofibrosis

23 sites incl. Gilbert

Sponsor: Disc Medicine, Inc

Sex: All·Age: 18+

Code: NCT05320198·Phase 1, Phase 2

Apply to this trial

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

for Non Hodgkin Lymphoma

8 sites incl. Chicago

Sponsor: Newave Pharmaceutical Inc

Sex: All·Age: 13+

Code: NCT04771572·Phase 1

Apply to this trial

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

for Myelofibrosis

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Sex: All·Age: 18+

Code: NCT06516406

Apply to this trial

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

for Myelofibrosis

6 sites incl. Duarte

Sponsor: Geron Corporation

Sex: All·Age: 18+

Code: NCT05371964·Phase 1

Apply to this trial

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

for Myeloproliferative Neoplasm

1 site in Irvine

Sponsor: University of California, Irvine

Sex: All·Age: 18+

Code: NCT05123365·Phase 1, Phase 2

Apply to this trial

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

for Myelofibrosis

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT05037760·Phase 2

Apply to this trial

Two Step Haplo With Radiation Conditioning

for Acute Lymphoblastic Leukemia

1 site in Philadephia

Sponsor: Thomas Jefferson University

Sex: All·Age: 18+

Code: NCT05031897·Phase 2

Apply to this trial

Methods of T Cell Depletion Trial (MoTD)

for Acute Myeloid Leukemia

Sponsor: University of Birmingham

Sex: All·Age: 16 - 70

Code: NCT04888741·Phase 2

Apply to this trial

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

for Acute Myeloid Leukemia

1 site in Rochester

Sponsor: Omar Aljitawi

Sex: All·Age: 18 - 75

Code: NCT03964506·EARLY_Phase 1

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

30 sites incl. Birmingham

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2

Apply to this trial

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

for Acute Leukemia

1 site in Minneapolis

Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All·Age: Up to 60

Code: NCT03314974·Phase 2

Apply to this trial

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for Cancer, Metastatic

67 sites incl. Birmingham

Sponsor: Massive Bio, Inc.

Sex: All·Age: All ages

Code: NCT03452774

Apply to this trial

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

for Myelofibrosis

1 site in Minneapolis

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: 55+

Code: NCT02934477

Apply to this trial

Quantitative MRI for Myelofibrosis

for Myelofibrosis

1 site in Ann Arbor

Sponsor: University of Michigan Rogel Cancer Center

Sex: All·Age: 18 - 99

Code: NCT01973881

Apply to this trial

Myelofibrosis clinical trials — common questions

Are myelofibrosis clinical trials free to join?

Yes. Participating in a myelofibrosis clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a myelofibrosis clinical trial?

Each myelofibrosis study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a myelofibrosis trial near me?

Use the location controls above. We'll show recruiting myelofibrosis trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many myelofibrosis trials are recruiting right now?

We're currently tracking roughly 37 recruiting myelofibrosis trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Myelofibrosis trials by city

Birmingham, AL Duarte, CA Ann Arbor, MI Boston, MA Chicago, IL Salt Lake City, UT Irvine, CA Los Angeles, CA Orange, CA Sacramento, CA

Related specialties

Oncology Blood cancer